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Abstract
Study design: This is a retrospective, diagnostic study, level IV.
Background: It appears to be necessary to identify prognostic markers for individual risk estimation for progression
and survival in patients with chordoma, a rare disease. Are pre-operative serum levels of C-reactive protein (CRP)
associated with disease progression and survival?
Methods: Survival rates of 24 patients (18 males, 6 females) (mean age 67 years (SD ± 16; range 20–85 years);
minimum follow-up 2 years, mean follow-up 5 years (SD ± 5; range 2–19 years)) with chordoma of the lower spine
and sacrum were assessed with a focus on pre-operative CRP levels.
Results: The survival rate of patients with pre-operative CRP level of >1.0 mg/dl was lower than that of patients
with a CRP level <1.0 mg/dl (p = 0.01). The estimated 10-year survival of patients with pre-operative CRP values <1.0
and >1.0 mg/dl was 76 and 25 %, respectively. CRP remained as an independent survival factor (p = 0.025; CI 95 %
1.0–2.6) in multivariable analysis.
Conclusions: Pre-operative CRP levels appear to be a biomarker for disease-specific survival in patients with
chordoma of the lumbar spine and sacrum. A validation of our finding with larger cohorts and integration of
putative risk factor would further elucidate CRP a surrogate for tumor progression.
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Background
Chordoma is one of the most common, primary malignant
bone tumors of the spine. About 50 % of these tumors
occur in the caudal spine, pelvis, and sacrum [1]. It is a
rare neoplastic disease (0.9/1,000,000 citizens/year) [2]
arising from embryonic notochord. Large databases reveal
5-year survival rates between 67 and 78 % [1, 3, 4]. Tumor
metastases are scarce; nevertheless, its primary local ag-
gressive growing leads to significant morbidity.
In previous clinical research, several prognostic factors
for an inferior survival have been speculated. Age [5],
tumor size >8 cm [6], the tumor site regarding the prox-
imal extent of the tumor, and local invasion into other
tissues [7] may influence survival [1, 8]. Local surgical
resection of the tumor [1, 4, 6] improves survival if the
localization involves the sacral bone but not the spine.
Local recurrence is higher when inadequate margins are
achieved [9–11]. Local recurrence is an important pre-
dictor of disease-related mortality [8, 12]. A more radical
surgical approach results in a decrease of recurrence to
a half or a third, at least in sacral chordomas [9, 13–15];
however, radical surgery compromises life quality mostly
for these elderly patients. The abovementioned prognos-
tic markers are mainly based on the clinical-pathological
findings. Therefore, pre-operatively and reliable prog-
nostic markers for individual risk estimation of recur-
rence and patient’s survival are needed.
In recent studies, the concept of the involvement of
systemic inflammation in cancer progression has been
postulated [16]. Specifically elevated C-reactive protein
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(CRP) as a marker of systemic inflammation [17] has
been found to be associated with decreased survival. C-
reactive protein (CRP) is a plasma protein mainly pro-
duced in the liver and triggered by interleukin IL-6 [18].
An elevated serum level of CRP (>1.0 mg/dl) is associ-
ated with both an increased risk in all cancer [19] and a
prognostic factor for survival and recurrence in different
types of both carcinoma, including breast, prostate,
colon, and hepatocellular carcinoma, and also bone and
soft-tissue sarcoma [20–23] including osteosarcoma,
Ewing’s sarcoma and chondrosarcoma. However, even
minor elevations of CRP (>0.3 mg/dl) implicate adverse
outcome on a variety of medical cardiovascular and non-
cardiovascular conditions [24]. An association of CRP and
a higher risk of death were seen in several cancers such as
lymphoma, multiple myeloma, esophageal carcinoma, and
colorectal cancer.
The impact on survival of pre-operative serum CRP
levels in patients with chordoma has not yet been eluci-
dated. This retrospective single-center study is an at-
tempt to evaluate pre-operative CRP in context with this
disease.
Methods
A review of our Institute’s bone and soft-tissue tumor
register revealed 34 patients ((24 males, 10 females) with
a mean age of 66 years (SD ± 16; range, 20–85 years)
and a consecutive mean follow-up (FU) of 5 years (SD ±
6; range, 2–19 years)) with diagnosed chordoma of the
lumbar spine and sacrum at our department from 1985
to 2012. The inclusion criteria for this retrospective
study were histologically verified chordoma and a mini-
mum follow-up of 2 years, unless death from the disease
had occurred within these 2 years. Pre-operative in-
house assessment of C-reactive protein was required to
avoid sample bias. Therefore, 10 patients had to be ex-
cluded. Histological specimens were analyzed within the
first 3 weeks postoperatively; all were primary chordo-
mas. The clinical records of the remaining 24 patients
(18 males, 6 females) (mean age 67 years (SD ± 16;
range, 20–85 years); mean FU 5 years (SD ± 5; range 2–
19 years)) were carefully reviewed. These patients form
the base of this study.
Tumor site in 5 (20 %) patients was in the lumbar
spine and in 19 (80 %) patients in the sacrum. The dis-
tribution of localization relative to S3 included 14 (58 %)
chordoma distal of S3 and 10 (42 %) chordoma proximal
of S3. Histologic diagnosis was confirmed by morph-
ology and immunohistochemical positivity of S-100,
CAM 5.2, and FU 5 at the local institute of pathology of
every bioptic specimen prior to surgery. Tumors were
subclassified into chondroid, conventional, and dediffer-
entiated chordoma. All patients had resections of the
tumor including 1 (4 %) incomplete vertebrectomy, 3
(12.5 %) total vertebrectomies, 18 (70 %) partial sacrec-
tomies, and 3 (12.5 %) resections of the coccygeal bone.
Resection margins were wide in 10 (42 %) patients, mar-
ginal in 12 (50 %) patients, and intralesional in 2 (8 %)
patients according to the Enneking criteria [25]. In seven
patients, postoperative radiotherapy was administered
when chordoma was localized in the lumbar spine or in
case of an intralesional resection. Two patients received
an irradiation of 50 Gy, four patients a dose of 60 Gy,
and one patient a dose of 66 Gy each in two Gy EDs
doses. Confounding diagnoses and conditions known to
be as well associated with increased CRP were assessed,
including all known tumors and cardiovascular risk fac-
tors (see Table 1). These were taken into account as con-
founding factors and were taken covariates in the
multivariable testing model.
Prior to this investigation, approval by the review
board of the Medical University of Vienna was obtained
and informed consent was routinely obtained from the
patients for further use in their files and registry data for
scientific purposes.
C-reactive protein
Patients’ blood was obtained before tumor resection by
venous puncture in 24 patients (18 males/6 females) with a
mean age of 67 years (SD 16 years; range, 20–85) and a
mean follow-up of 5 years (SD 7 years; range, 2–19). CRP
measurements were not expressly ascertained for study
purposes but performed as part of a pre-operative clinical
routine by a latex-enhanced immunoturbidimetric test
(Olympus AU 2700 CRP Latex, Beckman Coulter Inc., Brea,
California) according to the manufacturer’s instructions just
prior to surgery (day −1 or date of surgery). The respective
hardware specifications indicate a coefficient of variation of
1.65–3.79 % in a normal sensitivity setting, covering serum
CRP levels ranging from 0.02 to 45 mg/dl. Serum CRP
levels were categorized into below 1 mg/dl and >1 mg/dl.
Statistics
Statistical analyses of the data focused on disease-
specific survival in relation to CRP levels. CRP values
(mg/dl) are shown as means with standard deviation
(SD). CRP (<1.0 mg/dl and >1.0 mg/dl) values were
compared using an unpaired t test and Pearson correl-
ation analysis. Demographic (sex and age), surgical (sur-
gical method, tumor site, and resection margins), and
clinical-pathological variables (serum CRP-level, death
due to disease, recurrent disease) were examined. Age
and pre-operative serum CRP and fibrinogen and alka-
line phosphatase levels, as well as tumor size were
regarded as continuous variables; all other covariates
were modelled as categorical variables. Investigated end-
points of the study were death due to disease and recur-
rent disease. Survival probabilities were calculated with
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the Kaplan-Meier product limit estimator. To compare
survival functions of two or more groups, we applied the
log-rank test. Uni- and multivariable analyses were calcu-
lated by a Cox regression model. The multivariable model
was calculated with the covariates, age, gender, histologic
subtype, and possibly confounding diagnosis. All statistical
tests were two-sided. All analyses and graphical visualiza-
tions were performed using the Statistical Package for the
Social Sciences, Version 20.0 (SPSS, Chicago, Illinois). The
alpha level for all tests was set at p = 0.05, and p < 0.001
was considered highly significant. A power analysis was
performed using GraphPad StatMate (GraphPad Software
Inc., LaJolla, CA; version 2.00, 2004) and revealed that the
overall survival estimation comparing patients with CRP
values above 1.0 mg/dl to those with normal values had a
power of 0.45 to detect a minimal survival difference of
58 % with p = 0.05 (two-tailed). The respective survival
difference observed in this study was 59 %.
Results
The mean follow-up period was 5 years (median 4 years;
range, 0.5–19 years). The mean follow-up of 15 patients
surviving the disease was 6.7 years (median 6 years;
range, 2–19 years). Nine patients died due to disease
2.3 years (median 2.1 years; range, 0.5–4.4 years) after
surgery. Sixteen patients (67 %) developed recurrent
disease/disease progression. Two patients developed
metastatic disease including one skin metastasis of the
thigh and one lung metastasis.
C-reactive protein and survival
The mean pre-operative serum CRP level of all 24 pa-
tients was 1.22 mg/dl (SD 1.6 mg/dl). The pre-operative
CRP of 16 patients was <1.0 mg/dl (62 %) and the CRP
of eight patients >1.0 mg/dl (38 %).
A pre-operative CRP level >1.0 mg/dl was significantly
correlated with death due to disease (p = 0.006, r = 0.548).
Table 1 Demographics of patients with chordoma
Number Sex Age (years) Histology Tumor site Follow-up Death of
disease
CRP (mg/dl) Confounding diagnosis
Tumor CVD
1 Male 68 Conventional Prox S3 2.7 No 0.81 Hypertensive heart insufficiency II,
Hyperlipidemia
2 Male 85 Conventional Distal S3 11.1 No 0.10 Hypertension
3 Male 52 Conventional Distal S3 6.3 No 0.22 Hypertension
4 Male 79 Conventional Distal S3 3.7 No 0.85 Hypertension, type II diabetes, obesity
5 Male 81 Conventional Distal S3 2.8 No 1.18 Prostataca
6 Female 81 Conventional Distal S3 6.0 No 2.24
7 Female 79 Conventional Distal S3 1.4 Yes 0.87
8 Male 71 Conventional Prox S3 8.9 No 0.40
9 Male 82 Conventional Distal S3 1.6 Yes 0.00
10 Male 58 Chondroid Distal S3 4.2 No 0.40 Hypertension, hyperlipidemia
11 Male 84 Conventional Distal S3 4.1 Yes 1.10
12 Male 56 Chondroid Prox S3 8.1 No 0.15 Hypertension, obesity
13 Male 73 Conventional Prox S3 2.1 No 0.70
14 Male 35 Conventional Distal S3 1.6 Yes 0.90
15 Female 66 Conventional Prox S3 3.6 No 0.58
16 Male 62 Conventional Prox S3 4.3 No 3.30
17 Male 62 Conventional Prox S3 3.0 Yes 3.10
18 Male 20 Conventional Distal S3 0.5 Yes 0.81
19 Female 77 Conventional Prox S3 16.5 No 1.32 Basalioma
20 Female 77 Chondroid Prox S3 3.0 Yes 0.14
21 Male 60 Conventional Distal S3 18.8 No 1.95 Hypertension
22 Female 68 Dedifferentiated Prox S3 4.4 Yes 0.20
23 Male 52 Conventional Distal S3 2.1 No 7.60 Hypertension, renal insufficiency,
chon. Prostatitis
24 Male 77 Conventional Distal S3 1.3 Yes 8
Tumors (additional tumors)
CVD cardiovascular disease (meant to be confounders of increased CRP)
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Patients who died of the disease had higher pre-operative
CRP values than survivors (mean 2.3 mg/dl, SD ± 2.2 mg/dl
versus mean 0.5 mg/dl, SD ± 0.4 mg/dl) (p = 0.046).
Patients with a pre-operative CRP level of >1.0 mg/dl
had a lower survival rate than patients with a CRP
level <1.0 mg/dl (p = 0.01) (Fig. 1). The estimated 2-,
5-, and 10-year survival of patients with pre-operative
CRP values <1.0 mg/dl was 87, 76, and 76 % with
>1.0 mg/dl 62, 25, and 25 % respectively.
CRP was the strongest prognostic factor of survival in
univariable analysis (p < 0.0001) and remained significant
regarding survival (p = 0.025; CI 95 % 1.0–2.6) in multi-
variable analysis.
C-reactive protein and tumor progression
The mean CRP value of patients without recurrence was
0.6 mg/dl (SD ± 0.4 mg/dl; range, 0–0.9 mg/dl); the mean
CRP value of patients who developed recurrence was
1.5 mg/dl (SD ± 1.1 mg/dl; range, 0.1–3.3 mg/dl). There
was a trend in the difference between patients with
CRP <1.9 and >1.0 mg/dl in context with recurrence
(p = 0.09). The estimated 2-, 5-, and 10-year
recurrence-free survival of patients with pre-operative
CRP values <1.0 mg/dl was 87 %, 57 % and 46 %
with >1.0 mg/dl 57, 14, and 0 % respectively.
In univariable analysis CRP was significantly associated
with the incidence of tumor recurrence (p < 0.0001) (see
Table 2) and remained significant regarding recurrence
(p = 0.023; CI 95 % 1.0–2.3) in multivariable analysis.
Discussion
Chordoma is a rare and challenging disease with many
possible sequelae. Surgically, the radical resection was
considered, to the best of our knowledge, as state-of-
the-art treatment, but there are upcoming new thera-
peutical options, i.e., proton radiation. Surgical margins
in chordoma resection still seem to be the utmost de-
cisive factor concerning longer patient survival. How-
ever, the last and new century brought new perspectives
regarding tumor biology, microenvironment, and tumor
surveillance, and we are looking for prognostic markers
to estimate survival before manipulating our patients.
The concept of systemic inflammation (i.e., baseline
CRP) has been described to be important for disease-
prognostic purpose in many malignancies. In bone
sarcomas, both the survival [26–30] and recurrence have
shown significant associations with pre-operative CRP
values [20–23]. To the best of our knowledge, pre-
operative CRP values have not yet been associated with
outcomes for chordoma patients. Therefore, our aim
was to identify an association between pre-operative
CRP values and the survival in this rare disease.
The limitations of this study are certainly its retro-
spective design and the low number in the respective
groups compared, owing to the low incidence of this
rare disease, thereby reducing the statistical power of
Kaplan-Meier analyses to 0.45 and implying utmost crit-
ical interpretation of the conclusions deducted. Given
the present incidences of death in the group of patients
with CRP levels above 1.0 mg/dl, a power of 0.8 would
require a sample size of 14 patients with CRP levels
Fig. 1 Kaplan-Meier curves overall survival categorized into pre-
operative CRP levels <1.0 and >1.0 mg/dl
Table 2 Univariable analyses of clinical and oncological factors
with patient overall survival and recurrence




Tumor sizeb 0.64 0.668
Resection marginsa 0.44 0.379
Site (lumbar or sacral)a 0.946 0.985
Site (proximal or distal S3)a 0.402 0.895
Histologic subtypea, c 0.821 0.974
RTXa 0.992 0.74
Possibly confounding diagnosisa, d 0.003 0.024
Recurrencea 0.045 /
Pre-operative CRP levelsb <0.0001 <0.0001
Pre-operative aP levelsb 0.285 0.563
Pre-operative fibrinogen levelsb 0.506 0.71
aCalculated using log-rank test
bCalculated using Cox regression
cDifferentiation (conventional, chondroid, dedifferentiated)
dTumors and CV risk factors were taken into account
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above 1.0 mg/dl, thereby increasing the required patient
group by a factor of 2.3 to an estimated total of 49 patients,
a number rarely reported even in large scale studies.
Furthermore, the small number of patients was due to
our criteria to only include patients with a complete FU
and with in-house assessment of the CRP. As the CRP is
related to a lot of other clinical situations, as well as tu-
mors, this study was not designed to find patients with
tumors but to find patients with a high likeliness of a
poor outcome, which may be related to higher amount
of CRP. The covariate “confounding diagnosis” in the
multivariate analysis was introduced to take into account
the influence of other diseases on CRP as one factor.
In this presented study, CRP has the strongest prog-
nostic value for overall survival of all tested factors. A
CRP above 1.0 mg/dl was significantly linked to death
due to disease, and death due to disease mostly occurred
after two and a half years.
Several prognostic factors have been described to in-
fluence the outcome of chordoma patients. Recognized
prognostic parameters such as age, large tumor size, and
the localizations above S3 are all known to lead to a
poor outcome. We could not prove that age and
localization of tumor were co-factors for survival in our
collective. However, a trend towards low survival and
big tumor size was identified. Resection margins were
significantly associated with recurrence, which in conse-
quence was a significant prognostic factor for survival. A
wide en bloc resection with the removal of the biopsy
tract should be performed according to several authors
[9, 13–15]; however, radical surgery is often not feasible.
In consequence, prognostic factors could help physicians
confronted by the reality of these difficult decisions. One
large-sized attempt for a pre-operative disease-prognostic
grading scale in chordoma patients revealed age and
tumor-invasion as independent prediction factors, but
blood parameters were not taken into account [7]. Known
prognostic factors for adverse survival and recurrent
disease are mostly assessed after surgery. Determination
of serum CRP is possible prior to surgery, and moreover,
it is cheap, feasible, and part of routine-laboratory assess-
ment in almost every medical care unit.
There is a growing knowledge regarding inflammation
and its complex interplay with cancer. As CRP is known
as an acute-phase-protein in inflammation and many
types of cancer develop in a chronic-inflammatory
microenvironment, it may appear possible that infection
directs the processes of tumor growth, recurrence, and
metastatic disease [31]. CRP is mainly produced in hepa-
tocytes and is regulated by different interleukins (IL-6,
IL-1β). Il-6 is produced by macrophages [32] and is
known to be associated with tumorigenesis, cancer
growth, and invasion. Recently, CRP expression was en-
hanced in vascular smooth muscle cells after exposure
of mechanical strain and IL-6 [33]. This may explain that
local expansion in chordoma and any other kinds of
tumor leads to higher CRP levels in more aggressive tu-
mors by mechanical forces.
Even minor CRP elevations show a trend towards low
survival in this cohort of chordoma patients. These
minor CRP elevations may express a mild degree of tis-
sue stress, reflecting the presence of distressed cells ac-
cording to Kushner et al. [24].
Conclusions
To conclude, this finding of pre-operative CRP levels as a
prognostic marker in disease-specific survival for patients
with chordoma may be an important aspect for individual-
ized treatment in this disease that is characterized by high
recurrence and morbidity. A multicentered approach in-
volving CRP and other biomarkers to be tested in settings
with combined treatment including surgery and other up-
coming treatment options, i.e., carbon ions [34] based on
individual risk of patients could be the next step to find
new treatment algorithms for chordoma.
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